Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$615.8M
78M shares
52-week range
$6.13 – $14.96
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.72%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $429.8K | $283.3K | $239.2K | $190.9K | $65.4K | $0 | $43.5M | $311.7M |
| Cost of revenue | $396.8K | $373.2K | $204.8K | $148.9K | $3.7K | $205.6K | $3.2M | $36.0M |
| Gross profit | $33.0K | −$90.0K | $34.4K | $42.0K | $61.7K | −$205.6K | $40.3M | $275.7M |
| Gross margin | 7.7% | -31.8% | 14.4% | 22.0% | 94.3% | — | 92.7% | 88.5% |
| R&D | $18.8M | $11.1M | $13.4M | $13.1M | $10.7M | $13.2M | $3.9M | $19.3M |
| Operating income | −$26.9M | −$21.0M | −$27.2M | −$29.4M | −$30.6M | −$49.0M | −$22.4M | $150.1M |
| EBITDA | −$26.8M | −$20.9M | −$27.0M | −$29.4M | −$30.1M | −$46.2M | −$19.0M | $167.8M |
| Net income | −$26.8M | −$16.4M | −$22.0M | −$28.2M | −$29.7M | −$46.3M | −$17.9M | $163.1M |
| Net margin | -6242.4% | -5801.3% | -9207.7% | -14774.7% | -45409.9% | — | -41.2% | 52.3% |
| EPS (diluted) | -1.51 | -0.68 | -0.77 | -0.75 | -0.74 | -0.91 | -0.30 | 2.04 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $334M | $0.50 | $0.48–$0.51 | 4 |
| 2027 | $285M | $0.09 | $0.00–$0.17 | 4 |
| 2028 | $346M | $0.43 | $0.28–$0.52 | 4 |
| 2029 | $437M | $0.95 | $0.95–$0.96 | 2 |
Forward consensus · source: Financial Modeling Prep
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
www.cormedix.comNo one on the platform currently holds CRMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 152,200 | $1.9M |
| Execution date | Ratio |
|---|---|
| 2019-03-26 | 1-for-5reverse |
No one on the platform has traded CRMD yet.
| $974M |
| — |
| NBTXNanobiotix S.A. | $35.96 | -0.08% | $1.8B | — |
| PROKProKidney Corp. | $1.89 | +3.28% | $636M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 5.3× sales vs its 537.2× historical median P/S.
Fair value ≈ $769.68 · price $7.64 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CRMD $AKBA $FMS $DVA KCP responds to ESRD rule update last week… https://kidneycarepartners.org/press/kcp-calls-on-cms-to-strengthen-proposed-esrd-payment-rule-and-protect-patient-access-to-innovation/
View on StockTwits ↗$CRMD We need a new Congress first. A new Executive branch wouldn't hurt either.
View on StockTwits ↗$CRMD U.S. margin debt rose 54% to a record $1.4 trillion in May, signaling potential trouble amid surging leveraged ETF assets. Own what you own and that is not using margin to buy options on levered ETFs. If/When the SHTF, the margined super leveraged money borrowing casino addicts will be shredded and that is exactly what they deserve.
View on StockTwits ↗$CRMD 7 of the 60 people who engaged with this post are some sort of Fresenius affiliated manager of sorts…think this bodes well for MA adoption when time comes for VOLUME!
View on StockTwits ↗$CRMD it is like our pipeline is worthless and we only price in hemo. But Im not worried! Mr.Market will acknowledge and move accordingly. Our time line is just a little longer but nobody will care about that when we hit $30. Bearish = $15 Bullish = $30 Super bullish = $60+ As things look now we are in the middle when it come to adoption and execution. Most people here had the chance to sell all the way up to $17 but didnt, I wonder why? Maybe because we all know it is worth hell of a lot more than $17? Duuh. It still is...... I know it is hard to believe it when seeing todays SP. Do the math and you will see. If u cant do it yourself take some help with AI and you will see. Dont listen to these fake bears. Did you see them @ 14, 15, 16, 17? No, they come now when we are at the bottom. I wonder why ☺️ No better place to park my money! Enjoy the ride while it lasts 😉
View on StockTwits ↗$CRMD we are all tired of AI this and AI that but just for fun ask---regarding coremedix (crmd) is smart money accumulating or divesting this stock presently.
View on StockTwits ↗$CRMD Lower the price the better for stock buybacks! So long as before any possibly MA or DVA updates… Another poster had the observations based on Q1 the might repurchase last tradinging day of the month!
View on StockTwits ↗$CRMD Interesting comparing older versions of slide deck…was hopeful earlier on of MA announcement before July 1st…at least Joe gave updates tri-party discussions between top 5 MA + our top 3 customers ( + maybe DVA ?!)
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.